Breaking News Instant updates and real-time market news.

CMRE

Costamare

$5.65

-0.09 (-1.57%)

, WHR

Whirlpool

$139.39

0.35 (0.25%)

18:56
04/22/19
04/22
18:56
04/22/19
18:56

Fly Intel: After Hours Movers

UP AFTER EARNINGS: Costamare (CMRE) up 12.8%... Whirlpool (WHR) up 7.2%... Cadence Design Systems (CDNS) up 5.5%... Bright Scholar Education (BEDU) up 3.1%... Range Resources (RRC) up 1.7%... Western Alliance Bancorp (WAL) up 1.5%. ALSO HIGHER: Alder Biopharma (ALDR) up 2.7% after FDA accepted its BLA eptinezumab... Roku (ROKU) up 2.1% after being initiated with Positive at Susquehanna... Veracyte (VCYT) up 1.8% after receiving regulatory authority to offer Envisia Genomic Classifier in NY... Harpoon Therapeutics (HARP) up 1.6% after being initiated with Outperform at Baird. DOWN AFTER EARNINGS: Rambus (RMBS) down 6.1%. ALSO LOWER: Gritstone Oncology (GRTS) down 8.3% after equity offering... Guess (GES) down 1.1% after cutting dividend in half, affirming Q1 guidance... BHP (BHP) down 1.1% after being downgraded to Neutral at UBS. Movers as of 18:45ET.

CMRE

Costamare

$5.65

-0.09 (-1.57%)

WHR

Whirlpool

$139.39

0.35 (0.25%)

CDNS

Cadence Design

$64.23

0.87 (1.37%)

BEDU

Bright Scholar

$11.38

-0.105 (-0.91%)

RRC

Range Resources

$9.83

0.07 (0.72%)

WAL

Western Alliance

$43.36

-0.89 (-2.01%)

ALDR

Alder Biopharmaceuticals

$12.77

0.1 (0.79%)

ROKU

Roku

$58.19

1.5 (2.65%)

VCYT

Veracyte

$23.04

0.02 (0.09%)

HARP

Harpoon Therapeutics

$11.35

-1.68 (-12.89%)

RMBS

Rambus

$11.80

-0.1 (-0.84%)

GRTS

Gritstone Oncology

$14.57

0.86 (6.27%)

GES

Guess

$16.66

-0.41 (-2.40%)

BHP

BHP Group

$55.14

0.19 (0.35%)

  • 22

    Apr

  • 22

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 24

    Apr

  • 25

    Apr

  • 30

    Apr

  • 02

    May

  • 04

    May

  • 08

    May

  • 15

    May

  • 15

    May

  • 16

    May

  • 22

    May

  • 22

    May

  • 05

    Jun

  • 25

    Apr

CMRE Costamare
$5.65

-0.09 (-1.57%)

09/28/18
WELS
09/28/18
DOWNGRADE
Target $35
WELS
Market Perform
Triton International downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo analyst Michael Webber downgraded Triton International (TRTN) to Market Perform and lowered his price target for the shares to $35 from $44. The analyst downgraded the Box Lessor and Containership group saying headwinds from both the International Maritime Organization 2020 fuel regulations and the impact of tariffs have created "significant downside risks" for the stocks. The implementation of IMO 2020 fuel regulations will likely drive "significant losses" for most container lines, which will eventually weigh heavily on valuations and discount rates across the entire sector, Webber tells investors in a research note. Further, he believes higher fuel costs coupled with weaker container lines create trouble for the lessors. Along with Triton, Webber downgraded CAI International (CAI) and Costamare (CMRE) to Market Perform from Outperform and Seaspan (SSW) and Textainer (TGH) to Underperform from Market Perform. He keeps a Market Perform rating on Matson (MATX) with an unchanged price target of $35.
09/28/18
09/28/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. CITI CUTS TESLA TO SELL: Citi analyst Itay Michaeli downgraded Tesla (TSLA) to Sell from Neutral and lowered his price target for the shares to $225 from $356. The analyst is making a "risk/reward call" into the outcome of the SEC lawsuit against CEO Elon Musk. In a scenario where the suit leads to Musk's exit, the analyst says there is "little question" that the departure would likely cause harm to Tesla's brand, stakeholder confidence and fundraising. This would increase the risk of triggering a "downward confidence spiral" given the state of Tesla's balance sheet, Michaeli said. Even if Musk were to stay on after settling or prevailing, the analyst believes the "reputational harm" from the suit "might still prevent the stock from immediately returning to 'normal.'" SUNTRUST UPGRADES LOWE'S TO BUY: SunTrust analyst Keith Hughes upgraded Lowe's (LOW) to Buy from Hold and raised his price target to $138 from $110. The analyst cites the company's latest Q2 earnings and the analyst meeting with its management suggesting an "internally focused" turnaround progressing at a "consistent pace" over the next 2-3 years. Hughes adds that even though the stock has recently turned higher, it could rise as much as 50% if the company could reclaim just half of the SG&A difference with Home Depot (HD). STIFEL STARTS ZYNGA WITH A BUY: Stifel analyst Drew Crum initiated Zynga (ZNGA) with a Buy rating and a price target of $5. The analyst cites the "favorable industry for mobile gaming", with annualized mobile gaming revenue expected to increase by 17%. Crum also cites his expectations of greater visibility on its game pipeline and further opportunities to improve adjusted EBITDA. WELLS DOWNGRADES CONTAINERSHIP NAMES: Wells Fargo analyst Michael Webber downgraded the Box Lessor and Containership group saying headwinds from both the International Maritime Organization 2020 fuel regulations and the impact of tariffs have created "significant downside risks" for the stocks. He downgraded Triton International (TRTN), CAI International (CAI) and Costamare (CMRE), all to Market Perform from Outperform, and cut Seaspan (SSW) and Textainer (TGH) to Underperform from Market Perform. He kept a Market Perform rating on Matson (MATX) with an unchanged price target of $35. EVERCORE BOOSTS NVIDIA PRICE TARGET: Evercore ISI analyst C.J. Muse said he believes investors are now more appreciative of Nvidia's (NVDA) opportunity in creating the AI industry standard and the company's "positive feedback loop" within deep learning. Longer-term, he sees tremendous growth opportunities led by the new Turing architecture, which further entrenches Nvidia's high-end gaming moat and presents a "meaningful" opportunity in Inference, Muse said. The analyst, who sees Nvidia being poised to grow EPS at a 30-35% CAGR through 2020 and beyond, raised his price target on the stock to $400 from $300 and kept an Outperform rating on the shares.
09/28/18
WELS
09/28/18
DOWNGRADE
Target $6.5
WELS
Market Perform
Costamare downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo analyst Michael Webber downgraded Costamare to Market Perform and lowered his price target for the shares to $6.50 from $8. The analyst downgraded the Box Lessor and Containership group saying headwinds from both the International Maritime Organization 2020 fuel regulations and the impact of tariffs have created "significant downside risks" for the stocks. The implementation of IMO 2020 fuel regulations will likely drive "significant losses" for most container lines, which will eventually weigh heavily on valuations and discount rates across the entire sector, Webber tells investors in a research note. Further, he believes higher fuel costs coupled with weaker container lines create trouble for the lessors.
WHR Whirlpool
$139.39

0.35 (0.25%)

04/12/19
CLVD
04/12/19
NO CHANGE
CLVD
Neutral
Whirlpool estimates lowered on 'soft' Q1 shipments at Cleveland Research
Cleveland Research lowered its estimates for Whirlpool after its channel work indicated "soft" industry shipments through Q1. Feedback on Whirlpool suggests the company's unit performance may be similar to the market in Q1, which is likely to be down 5%-7%, Cleveland said earlier in a research note. The firm believes sell-through in the appliance category remained weak through most of March. It also continues to see concern around incremental promotions for the appliance category through 2019. Cleveland reduced its 2019 earnings per share estimate for Whirlpool to $14.45 from $14.60 and keeps a Neutral rating on the stock.
01/30/19
01/30/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Allergan (AGN) downgraded to Sector Perform from Outperform at RBC Capital and to Equal Weight from Overweight at Morgan Stanley. 2. Whirlpool (WHR) downgraded to Underperform from Sector Perform at RBC Capital and to Market Perform from Outperform at Raymond James. 3. Olin (OLN) and Westlake Chemical (WLK) were downgraded to Reduce from Neutral at Nomura Instinet. 4. Coherent (COHR) downgraded to Hold from Buy at Needham with analyst James Ricchiuti citing the compnay's in-line Q1 results and "much weaker" than expected Q2 guidance along with withdrawn outlook FY19. 5. Carnival (CCL) downgraded to Hold from Buy at Standpoint Research. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/15/19
BUCK
04/15/19
NO CHANGE
Target $135
BUCK
Neutral
AHAM 6 appliance shipments drop 6% in March, says Buckingham
The Association of Home Appliance Manufacturers reported March appliance shipments were down 6% while total appliances were down 4%, Buckingham analyst Megan McGrath tells investors in a research note titled "AHAM Data for March Continues To Reflect Tariff." The overall unit decline was generally in line with the analyst's expectations, but she notes that weakness in the month extended beyond the Laundry category, which she calls "somewhat surprising." McGrath maintained her 4% North America revenue growth estimate for Whirlpool's Q1, as she continues to expect the company to outperform industry data and benefit from higher pricing. The analyst keeps a Neutral rating on Whirlpool with a $135 price target.
01/30/19
RBCM
01/30/19
DOWNGRADE
Target $111
RBCM
Underperform
Whirlpool downgraded to Underperform from Sector Perform at RBC Capital
RBC Capital analyst Mike Dahl downgraded Whirlpool to Underperform with an unchanged price target of $111 after the stock rallied 10% in spite of the disappointing Q4 earnings and a soft FY19 guidance. The analyst believes that the rally was driven by the perception of the guidance being conservative, since it did not assume the impact of buybacks and also modeled "healthy level of cost inflation assumptions including tariffs". While he sees these areas as "supportive", Dahl believes the that uncertainty in industry market share and pricing dynamics for the company warrant caution.
CDNS Cadence Design
$64.23

0.87 (1.37%)

02/20/19
DADA
02/20/19
NO CHANGE
Target $62
DADA
Buy
Cadence Design price target raised to $62 from $52 at DA Davidson
DA Davidson analyst Thomas Diffely raised his price target on Cadence Design to $62 and kept his Buy rating, saying the company's Q4 earnings beat and better than expected guidance are driven by the "key technology inflections in data center, 5G, auto, AI, VR/AR", and other businesses. The analyst notes that while the semiconductor and system customers of Cadence Design are suffering from investment delays, the company is making progress on its total addressable market expansion strategy, with added "focus on adjacencies in the aerospace & defense, auto, and medical verticals." Diffely adds that macro concerns in China have had no impact on design activity in the region.
03/14/19
NEED
03/14/19
NO CHANGE
Target $64
NEED
Cadence Design price target raised to $64 from $60 at Needham
Needham analyst Richard Valera raised his price target on Cadence Design to $64 and kept his Buy rating after holding talks with its CFO John Wall and Investor Relations director Alan Lindstrom. The analyst says the discussions were highlighted by the management's view of "robust demand" that the company is seeing across numerous verticals. Valera also believes that Cadence Design is positioned "for continued share gains in digital", with good pricing power and margin expansion.
02/20/19
NEED
02/20/19
NO CHANGE
Target $60
NEED
Buy
Cadence Design price target raised to $60 from $50 at Needham
Needham analyst Richard Valera raised his price target on Cadence Design to $60 and kept his Buy rating after its Q4 earnings beat and a "healthy" FY19 guidance that "solidly exceeded consensus". The analyst cites the management's view of continued investment in design tools by companies involved in AI/ML, cloud/datacenter, 4G, and auto technologies, many of which are facing near-term challenges. Valera also points to Cadence Design's China business staying robust and growing to 10% of 2018 revenue vs. 9% in 2017.
04/10/19
KEYB
04/10/19
INITIATION
KEYB
Sector Weight
Cadence Design resumed with a Sector Weight at KeyBanc
KeyBanc analyst Jason Celino resumed coverage of Cadence Design with a Sector Weight on valuation. Nonetheless, the analyst acknowledges that Cadence is a "high-quality" company, with a strong capital allocation strategy, and also benefiting from broad-based EDA tailwinds and executing well.
BEDU Bright Scholar
$11.38

-0.105 (-0.91%)

11/12/18
JPMS
11/12/18
NO CHANGE
Target $48
JPMS
Overweight
Chinese education sector selloff unwarranted, says JPMorgan
The results reported mid-year in the Chinese education sector have not deteriorated sufficiently to warrant the share price performance, JPMorgan analyst Leon Chik tells investors in a research note. The analyst points out that the average education company under his coverage is down 25%-30% since the end of May. He believes this may be due to greater uncertainty over the future due to a slowing economy and an increase in government regulations. New regulations provide short term challenges but help speed up market consolidation as larger operators can cope with changes better, Chik tells investors in a research note. The analyst's top after school tutorial picks are TAL Education (TAL) and New Oriental Education (EDU). He also has an Overweight rating on Bright Scholar Education (BEDU). Chik lowered his price target for TAL to $48 from $58, for New Oriental to $85 from $98 and for Bright Scholar to $15 from $20.
12/03/18
GSCO
12/03/18
INITIATION
GSCO
Neutral
Bright Scholar initiated with a Neutral at Goldman Sachs
Goldman Sachs started Bright Scholar Education Holdings with a Neutral rating and $12.50 price target.
03/28/19
GSCO
03/28/19
UPGRADE
GSCO
Buy
Bright Scholar upgraded to Buy from Neutral at Goldman Sachs
03/29/19
GSCO
03/29/19
UPGRADE
Target $12.8
GSCO
Buy
Goldman upgrades Bright Scholar to Buy, says kindergarten worries overdone
Goldman Sachs analyst Christine Cho upgraded Bright Scholar (BEDU) to Buy from Neutral, stating that she believes the market is overly concerned about the growth outlook for its kindergarten business and the company's ability to consolidate. She notes that Bright Scholar shares have underperformed as much as RYB Education (RYB), which is purely exposed to the kindergarten business, even though Bright Scholar's kindergarten business accounted for only 23% of the company's revenue and 28% of gross profit in FY18. Cho keeps a $12.80 price target on Bright Scholar shares.
RRC Range Resources
$9.83

0.07 (0.72%)

02/11/19
LTCO
02/11/19
NO CHANGE
LTCO
Ladenburg says Buy Range Resources on 'solid' 2018 reserve replacement
Ladenburg analyst Michael Schmitz reiterated a Buy rating and $17 price target on Range Resources, citing the company's 18% increase in proved reserves and the company's commitment to generating competitive free cash flow.
01/08/19
RHCO
01/08/19
NO CHANGE
Target $12
RHCO
Hold
Range Resources price target lowered to $12 from $20 at SunTrust
SunTrust analyst Welles Fitzpatrick lowered his price target on Range Resources to $12 and kept his Hold rating after the company pre-released its expected Q4 output at 2.15BCFE/D - below consensus of 2.27BCFE/D - yesterday, citing a "larger than expected impact from the previously announced processing downtime." The analyst notes that while the production update as offset by reduction in capital expenditures to $195M from $215M forecast, he is adjusting his net asset value to reflect the "slower expected development plan going forward and lower comps". Fitzpatrick adds that although Range Resources offers "premier assets", its higher relative level of net debt and premium valuation justify a Neutral stance
03/02/19
TDSI
03/02/19
DOWNGRADE
Target $11
TDSI
Hold
Range Resources downgraded to Hold from Buy at TD Securities (Wednesday)
TD Securities analyst Aaron Bilkoski downgraded Range Resources on Wednesday, February 27, to Hold from Buy and lowered his price target for the shares to $11 from $15.
04/09/19
COWN
04/09/19
INITIATION
Target $14
COWN
Outperform
Range Resources initiated with an Outperform at Cowen
Cowen analyst David Deckelbaum started Range Resources with an Outperform rating and $14 price target. At strip pricing, the analyst believes Range can deliver annual production growth of 6.5% through 2023 with cumulative free cash generated of $1B. Further, he notes the company is "actively addressing" its "largest hurdle," leverage.
WAL Western Alliance
$43.36

-0.89 (-2.01%)

10/22/18
RBCM
10/22/18
NO CHANGE
Target $61
RBCM
Outperform
Western Alliance price target lowered to $61 from $68 at RBC Capital
RBC Capital analyst Jon Arfstrom lowered his price target on Western Alliance to $61 to reflect the "recent change in peer multiples" but also kept his Outperform rating following a "solid" set of results in Q3. The analyst notes that while the management was somewhat cautious in terms of its 2019 growth and margins expectations, the outlook was still "strong". Arfstrom added that he "appreciates" Western Alliance's continued "ability to produce above peer growth and returns" along with its strong credit quality.
01/15/19
SBSH
01/15/19
UPGRADE
Target $53
SBSH
Buy
Western Alliance upgraded to Buy from Neutral at Citi
Citi analyst Arren Cyganovich upgraded Western Alliance Bancorp to Buy while lowering his price target for the shares to $53 from $56.
10/23/18
RHCO
10/23/18
NO CHANGE
Target $63
RHCO
Buy
Western Alliance price target lowered to $63 from $70 at SunTrust
SunTrust analyst Michael Young lowered his price target on Western Alliance to $63 to reflect the contraction in industry multiples but also keeps his Buy rating after the bank's Q3 results. The analyst notes that Western Alliance posted better net interest income growth than its peers thanks to a lower loan to deposit ratio and expects its net interest margins to remain supported.
10/21/18
KBWI
10/21/18
NO CHANGE
Target $75
KBWI
Outperform
Western Alliance should be bought on 'misguided' selloff, says Keefe Bruyette
Keefe Bruyette analyst Christopher McGratty says Friday's 8% selloff in shares of Western Alliance Bancorporation was "misguided." The pullback related to a "misunderstanding" of the company's outlook, which effectively "blessed" 2019 consensus estimates, McGratty tells investors in a research note. He recommends adding to positions in Western Alliance, noting that his estimates are unchanged and the stock is now trading at "just" 11 times his 2019 numbers. The analyst keeps an Outperform rating on the shares with a $75 price target.
ALDR Alder Biopharmaceuticals
$12.77

0.1 (0.79%)

11/28/18
PIPR
11/28/18
NO CHANGE
Target $28
PIPR
Overweight
Alder Biopharmaceuticals's epti to benefit from SubQ profile, says Piper Jaffray
Piper Jaffray analyst Danielle Brill kept her Overweight rating and $28 price target on Alder Biopharmaceuticals following her meeting with its CEO Robert Azelby. The analyst says that the discussion of the recent launch of competitor SubQ anti-CGRP mAbs for migraine prevention raised the profile of its eptinezumab, noting that "given epti's rapid onset of effect and deep magnitude of response, the company believes there will be demand" for epti. Brill still sees the program's BLA submission on track for Q1 of 2019 with the potential launch coming in Q1 of 2020.
04/04/19
PIPR
04/04/19
NO CHANGE
PIPR
Overweight
Piper Jaffray stays Overweight on Alder Biopharma, Amgen after Novartis filing
Piper Jaffray analyst Christopher Raymond maintains his Overweight rating on Alder Biopharma (ALDR) and Amgen (AMGN) after the filing by Novartis (NVS) alleging legal dispute with the latter about their migraine collaboration. The analyst says that Novartis tried to beat Amgen to the punch after entering agreement with Alder to manufacture eptinezumab, which prompted Amgen to terminate their commercialization agreement. Raymond adds that a resolution of this dispute could take a year or more but believes that investors may conclude that the spat reflects the value of anti-CGRP assets.
04/18/19
PIPR
04/18/19
NO CHANGE
PIPR
Teva gains ground on Amgen in latest migraine survey, says Piper Jaffray
Following of survey of 99 neurologists done by his firm's partner Spherix Global Insights, Piper Jaffray analyst Christopher Raymond maintains an Overweight rating on Amgen (AMGN) and a Neutral rating on Teva Pharmaceutical (TEVA). The migraine survey indicates Eli Lilly's (LLY) Emgality is lagging and that Teva's Ajovy appears to be gaining ground on Amgen's Aimovig across numerous metrics, Raymond tells investors in a research note. While one data point does not a trend make, this move warrants close attention, especially given the increased significance assigned to Aimovig with respect to Amgen sentiment, says the analyst. Raymond, however, remains cautious on Teva shares given the" lack of clarity regarding when/where EBITDA will hit a trough." On the R&D side, the analyst notes that Overweight-rated Alder Biopharmaceuticals' (ALDR) eptinezumab "appears to be particularly top-of-mind among migraine specialists."
02/25/19
PIPR
02/25/19
NO CHANGE
Target $28
PIPR
Overweight
Piper Jaffray maintains positive view of Alder Biopharmaceuticals' eptinezumab
Piper Jaffray analyst Danielle Brill kept her Overweight rating and $28 price target on Alder Biopharmaceuticals after its Q4 results and update on eptinezumab this evening. The analyst maintains a positive view on the program and contends that "eptinezumab is the best suited agent for the most debilitated migraine patients", adding that the company could generate peak revenues of over $1B if it were to capture just the severe subset of patients.
ROKU Roku
$58.19

1.5 (2.65%)

04/08/19
SBSH
04/08/19
DOWNGRADE
Target $50
SBSH
Sell
Citi downgrades Roku to Sell with $50 target after 110% year-to-date rally
Citi analyst Mark May downgraded Roku to Sell from Neutral and lowered his price target for the shares to $50 from $53. The stock is up 110% year-to-date and near all-time highs, May tells investors in a research note. The analyst notes Roku trades at a 70% premium to peers and believes that recent changes in the over-the-top streaming landscape could create greater competition. Further, Roku's Platform segment revenue growth could be impacted this year due to tough comps, May tells investors in a research note.
04/12/19
RHCO
04/12/19
NO CHANGE
RHCO
Disney+ not a 'strong alternative' to Netflix, says SunTrust
SunTrust analyst Matthew Thornton keeps his Buy rating on Netflix (NFLX) after Disney's (DIS) Disney+ investor day presentation, saying that while he continues to view the platform posing incremental competition for new subscriber adds, he expects it to be "manageable". The analyst notes that the Disney+ event contained "no big surprises in terms of pricing, timing, availability, and content", adding that the accelerated cord-cutting from the launch should also be positive for Netflix, which offers a "much broader range of content". Thornton further states that Disney+ should be a "modest incremental positive" for his Buy-rated Roku (ROKU) as it will be available for sale on its platform given its "potential for direct monetization."
04/22/19
SUSQ
04/22/19
INITIATION
Target $80
SUSQ
Positive
Roku initiated with a Positive at Susquehanna
Susquehanna analyst Shyam Patil initiated Roku with a Positive and $80 price target.
04/08/19
04/08/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. General Electric (GE) downgraded to Underweight from Neutral at JPMorgan with analyst Stephen Tusa saying with the stock up 38% year-to-date, many investors are underestimating the severity of the challenges and underlying risks at GE, while overestimating the value of "small positives." 2. Starbucks (SBUX) downgraded to Neutral from Buy at UBS with analyst Dennis Geiger saying the risk/reward on shares "appears balanced" with the stock up 55% since June. 3. Boeing (BA) downgraded to Neutral from Buy at BofA/Merrill with analyst Ronald Epstein citing the company's announcement that it will cut 737 production rates to 42 per month from 52 per month, which he takes to likely mean that the 737 delay could last longer than previously expected. 4. Micron (MU) downgraded to Market Perform from Outperform at Cowen with analyst Karl Ackerman saying his field work indicates Micron's profitability will decline again in calendar year 2020. 5. Roku (ROKU) downgraded to Sell from Neutral at Citi with analyst Mark May saying the stock is up 110% year-to-date and near all-time highs. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
VCYT Veracyte
$23.04

0.02 (0.09%)

01/29/19
LSCM
01/29/19
NO CHANGE
Target $7
LSCM
Buy
OncoCyte price target raised to $7 from $4 at Lake Street
Lake Street analyst Thomas Flaten said OncoCyte's (OCX) R&D Validation study results are in line with previously published data and better than requirements for commercialization. He noted that a company-sponsored survey of 250 chest physicians previously indicated they would require minimum sensitivity and specificity of 85% and 35%, respectively. Flaten believes the fact that the study results were generated solely on biomarkers creates a favorable competitive advantage relative to competitors Veracyte (VCYT) and BioDesix, he added. Stating that he thinks today's results provide strong evidence the company can move forward with a commercially viable product, Flaten raised his price target to $7 from $4 and keeps a Buy rating on OncoCyte shares.
10/31/18
JANY
10/31/18
UPGRADE
JANY
Buy
Veracyte upgraded to Buy from Neutral at Janney Montgomery Scott
07/24/18
PIPR
07/24/18
NO CHANGE
Target $11
PIPR
Neutral
Veracyte price target raised to $11 from $7 at Piper Jaffray
Piper Jaffray analyst William Quirk raised his price target for Veracyte to $11 following the company's Q2 sales beat and increased 2018 guidance. Veracyte is entering a "new multi-faceted growth cycle" and deserves a premium multiple, Quirk tells investors in a post-earnings research note. The analyst keeps a Neutral rating on the shares but has a "positive bias." He views the new guidance as "not only achievable but potentially beatable."
01/04/19
BTIG
01/04/19
NO CHANGE
Target $17
BTIG
Buy
Veracyte price target raised to $17 from $15 at BTIG
BTIG analyst Sung Ji Nam raised his price target on Veracyte (VCYT) to $17 and kept the Buy rating on the shares after its announced long term partnership with Johnson & Johnson (JNJ) yesterday. The analyst says the collaboration aims to accelerate the development of the first nasal swab test for early lung cancer detection and involve the two companies sharing existing data and samples from clinical studies. Sung Ji Nam states that the deal should lead to acceleration of next -gen Percepta launch, adding that the nasal swab test development could quadruple the company's total addressable market value in the U.S. alone.
HARP Harpoon Therapeutics
$11.35

-1.68 (-12.89%)

03/05/19
ADAM
03/05/19
INITIATION
Target $24
ADAM
Buy
Harpoon Therapeutics initiated with a Buy at Canaccord
Canaccord analyst Arlinda Lee initiated Harpoon Therapeutics with a Buy as she sees solid prospects for it lead drug candidate TriTac, which engages T cells to harness the body's immune system to treat cancer and other diseases. Lee has a $24 price target on Harpoon Therapeutics shares.
03/05/19
03/05/19
INITIATION
Target $23

Outperform
Wedbush bullish on Harpoon Therapeutics, initiates with an Outperform
As previously reported, Wedbush analyst Robert Driscoll started coverage of Harpoon Therapeutics with an Outperform rating and $23 price target. The analyst sees its next-generation bispecific platform, TriTACs, as offering critical advantages over current bispecific approaches, including an extended half-life, small size to allow for increased tumor penetration, and activity at low levels of tumor antigen expression. Driscoll also believes the company's initial focus on clinically-validated targets allows for a high likelihood of success, and expects the platform to drive additional value as novel candidates move into the clinic going forward.
04/22/19
BARD
04/22/19
INITIATION
Target $25
BARD
Outperform
Harpoon Therapeutics initiated with an Outperform at Baird
Baird analyst Michael Ulz started Harpoon Therapeutics with an Outperform rating and $25 price target.
03/05/19
ADAM
03/05/19
INITIATION
Target $24
ADAM
Buy
Harpoon Therapeutics initiated with a Buy at Canaccord
Canaccord initiated Harpoon Therapeutics with a Buy and $24 price target.
RMBS Rambus
$11.80

-0.1 (-0.84%)

10/23/18
ROTH
10/23/18
NO CHANGE
Target $13
ROTH
Buy
Rambus price target lowered to $13 from $18 at Roth Capital
Roth Capital analyst Suji Desilva lowered his price target for Rambus to $13 from $18 to reflect broader semiconductor stock weakness. The analyst reiterates a Buy rating on the shares.
01/23/19
BNCH
01/23/19
NO CHANGE
Target $15
BNCH
Buy
Rambus royalties shouldn't be hurt near-term by DRAM prices, says Benchmark
In a preview of Rambus' upcoming earnings report, Benchmark analyst Gary Mobley noted that its royalties are mostly fixed and shouldn't be impacted much in the near-term due to falling memory prices or sales, other than a $15M step down from SK Hynix in FY19. The analyst, who expects Rambus to reiterate flat FY19 revenue and billings, keeps a Buy rating on the stock with a price target of $15.
10/30/18
DBAB
10/30/18
NO CHANGE
Target $13
DBAB
Buy
Rambus price target lowered to $13 from $16 at Deutsche Bank
Deutsche Bank analyst Sidney Ho lowered his price target for Rambus to $13 following the company's "largely in-line" Q3 results and guidance. However, Rambus' strategic shift and resulting change to 2019 growth expectations were "somewhat unexpected," Ho tells investors in a post-earnings research note. While RSD uncertainty is a lasting concern for investors, this is now de-risked with the company shifting its focus of resources into new areas in the semiconductor and embedded security markets, says Ho. He keeps a Buy rating on Rambus.
06/29/18
BNCH
06/29/18
NO CHANGE
BNCH
Buy
Rambus CEO resignation seems related to personal matter, says Benchmark
Benchmark analyst Gary Mobley reiterated his Buy rating on Rambus shares following the departure of CEO Ron Black, which he said seems to be related to a personal matter and not an indication of bad execution. While Rambus did not officially re-affirm comfort in FY18 consensus, the company's press release emphasized that Black's departure is not a reflection of the company not executing on its growth initiatives, added Mobley.
GRTS Gritstone Oncology
$14.57

0.86 (6.27%)

03/14/19
RAJA
03/14/19
INITIATION
RAJA
Outperform
Gritstone Oncology initiated with an Outperform at Raymond James
Raymond James analyst Dane Leone initiated Gritstone Oncology with an Outperform rating and a price target of $20. The analyst has three key reasons for recommending the stock: First, GRANITE-001 will be a proof of concept regarding the anti-tumor effect of highly stimulated CD8+ T cells. Second, "development of the MHC Class II EDGE model balances the risks with the current reliance of CD8+ T cells within the GRANITE-001 and SLATE-001 programs." Third, Leone believes the technical approach to neoantigen vaccine design that Gritstone is pursuing is "likely to be more effective than competitor efforts employing peptide vaccination approaches."
12/11/18
BTIG
12/11/18
NO CHANGE
Target $31
BTIG
Buy
Gritstone Oncology price target raised to $31 from $26 at BTIG
BTIG analyst Thomas Shrader raised his price target on Gritstone Oncology to $31 and kept his Buy rating after the company's "announced start of lead optimization of a neoantigen-targeted bi-mAb designed to bring T-Cells to neoantigen targets on tumors." The analyst has a favorable view of this program and sees its selection of specific neoantigen targets for lead optimization as a "significant step in the development of neoantigen-targeted therapeutics."
03/27/19
BREN
03/27/19
INITIATION
Target $30
BREN
Buy
Gritstone Oncology initiated with a Buy at Berenberg
Berenberg analyst Shanshan Xu initiated Gritstone Oncology with a Buy rating and $30 price target, stating that Gritstone's neoantigen platform may represent the "best-in-class" algorithm for identifying bona fide neoantigens. The company also has a vaccine "prime-and-boost" platform that may also be differentiated, Xu noted.
03/07/19
HCWC
03/07/19
INITIATION
Target $17
HCWC
Buy
Gritstone Oncology initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth started Gritstone Oncology with a Buy rating and $17 price target. The company's core technology is its Gritstone EDGE artificial intelligence platform, which has demonstrated an up to nine-fold increased prediction accuracy for identifying potential tumor neoantigens, Ramakanth tells investors in a research note. Further, Granite-001 has the potential to become the first "universal" vaccine that can be used across the full range of cancer indications, which could significantly increase its market potential, says the analyst.
GES Guess
$16.66

-0.41 (-2.40%)

02/07/19
JEFF
02/07/19
UPGRADE
Target $24
JEFF
Buy
Jefferies upgrades Guess to Buy following recent share pullback
Jefferies analyst Janine Stichter upgraded Guess to Buy from Hold with an unchanged price target of $24. The recent pullback in the stock puts the company's multiple below its historical average and peers, Stichter tells investors in a research note. This presents an opportunity to own one of the few remaining retailers with both top-line growth and potential for margin expansion, the analyst writes. Further, she views the management change as an opportunity, not a sign of current weakness. Stichter also sees a "substantial runway for growth ahead" in Europe and Asia for Stichter, while pointing out that data suggest inflecting North America momentum.
02/07/19
JEFF
02/07/19
UPGRADE
Target $24
JEFF
Buy
Guess upgraded to Buy from Hold at Jefferies
Jefferies analyst Janine Stichter upgraded Guess to Buy with a $24 price target.
02/07/19
02/07/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Saia (SAIA) upgraded to Buy from Hold at Deutsche Bank with analyst Amit Mehrotra saying after meeting with management, he is incrementally more confident in Saia's ability to generate double-digit revenue growth this year. 2. Guess (GES) upgraded to Buy from Hold at Jefferies with analyst Janine Stichter saying the recent pullback in the stock puts the company's multiple below its historical average and peers. 3. Spirit Airlines (SAVE) upgraded to Buy from Neutral at Goldman Sachs with analyst Catherine O'Brien saying she expects passenger revenue trends for the company in the first half of the year to be stronger than previously anticipated. 4. MacroGenics (MGNX) upgraded to Buy from Sell at Citi with analyst Yigal Nochomovitz saying additional Phase 1 readouts in 2019 should provide further stock momentum for MacroGenics. 5. Cognizant (CTSH) upgraded to Outperform from Market Perform at BMO Capital with analyst Keith Bachman citing the company's FY19 revenue growth outlook and a positive management transition. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/21/19
JEFF
03/21/19
NO CHANGE
Target $24
JEFF
Buy
Guess in penalty box but fundamentals healthy, says Jefferies
While Guess shares will be in the penalty box near-term as an inventory overhang weighs on margins, its fundamentals remain healthy, Jefferies analyst Janine Stichter tells investors in a research note. The analyst expects CEO Carlos Alberini's return to be a positive catalyst for Guess and that his first earnings call as CEO was a strong one. Significant market share potential remains in Europe and Asia for Guess while North America appears to be gaining momentum, says Stichter. She keeps a Buy rating on the shares with a $24 price target.
BHP BHP Group
$55.14

0.19 (0.35%)

03/07/19
SOCG
03/07/19
DOWNGRADE
SOCG
Hold
BHP Group downgraded to Hold from Buy at Societe Generale
02/19/19
GSCO
02/19/19
DOWNGRADE
GSCO
Neutral
BHP Group downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst Paul Young downgraded BHP Group to Neutral from Buy after the company reported 1H FY19 underlying earnings that were down 23% half-over-half due to a weak operating performance mainly across copper and coal. The company's production, capex, growth projects and unit costs guidance implies a very strong operating performance in the second half, said Young, who cites valuation for his rating change. He decreased his FY19 EPS estimate by 4% on the slightly weaker result and higher thermal coal costs and revised his price target on BHP shares to A$36.20.
02/12/19
02/12/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. BHP Billiton (BHP) downgraded to Neutral from Buy at Goldman Sachs. 2. Gilead (GILD) downgraded to Neutral from Buy at Citi and to Market Perform from Outperform at Wells Fargo. 3. Cisco (CSCO) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst James Faucette saying Cisco's multiple has meaningfully expanded over the past 1.5 years as estimates and expectations have built in a likely benefit from security-driven networking. 4. Take-Two (TTWO) downgraded to Underperform from Market Perform at BMO Capital with analyst Gerrick Johnson saying that after a 2-year "hype machine" blast for its Red Dead Redemption 2 title and its "strong" premier, the buzz around the game has "dissipated markedly." 5. Fastenal (FAST) downgraded to Sector Weight from Overweight at KeyBanc with analyst Steve Barger saying he continues to view the company as a "best-in-class" distributor with a "sizable first-mover advantage" in OnSite and Vending, but he finds the stock's risk/reward as more balanced near his prior price target of $62. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/22/19
UBSW
04/22/19
DOWNGRADE
UBSW
Neutral
BHP Group downgraded to Neutral from Buy at UBS

TODAY'S FREE FLY STORIES

T

AT&T

$31.79

0.17 (0.54%)

, CMCSA

Comcast

$43.54

0.29 (0.67%)

16:48
05/19/19
05/19
16:48
05/19/19
16:48
On The Fly
Box Office Battle: 'John Wick' beats 'Avengers: Endgame' with $57M opening »

"Box Office Battle" is…

T

AT&T

$31.79

0.17 (0.54%)

CMCSA

Comcast

$43.54

0.29 (0.67%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$52.65

0.85 (1.64%)

LGF.A

Lionsgate

$15.60

1.99 (14.62%)

DIS

Disney

$135.04

-0.46 (-0.34%)

VIAB

Viacom

$28.45

-0.09 (-0.32%)

VIA

Viacom

$33.33

-0.05 (-0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 23

    May

  • 23

    May

  • 05

    Jun

  • 06

    Jun

  • 10

    Jun

  • 12

    Jun

  • 24

    Jun

  • 24

    Jul

F

Ford

$10.29

-0.1 (-0.96%)

, FCAU

Fiat Chrysler

$14.84

-0.01 (-0.07%)

16:11
05/19/19
05/19
16:11
05/19/19
16:11
Periodicals
Fiat Chrysler Ram gaining on GM, Ford pickups, WSJ reports »

The growing popularity of…

F

Ford

$10.29

-0.1 (-0.96%)

FCAU

Fiat Chrysler

$14.84

-0.01 (-0.07%)

GM

General Motors

$37.00

-0.36 (-0.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 04

    Jun

  • 05

    Jun

  • 24

    Jul

  • 31

    Jul

  • 01

    Aug

  • 23

    Oct

RMD

ResMed

$112.81

-0.635 (-0.56%)

16:07
05/19/19
05/19
16:07
05/19/19
16:07
Hot Stocks
ResMed reveals demographic, clinical factors affect adherence to PAP therapy »

ResMed revealed several…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

GOOGL

Alphabet Class A

$1,168.28

-15.39 (-1.30%)

, GOOG

Alphabet

$1,161.89

-16.89 (-1.43%)

13:48
05/19/19
05/19
13:48
05/19/19
13:48
Periodicals
Google suspends some business with Huawei, Reuters reports »

Alphabet's Google…

GOOGL

Alphabet Class A

$1,168.28

-15.39 (-1.30%)

GOOG

Alphabet

$1,161.89

-16.89 (-1.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 19

    Jun

  • 27

    Oct

BA

Boeing

$354.99

0.5 (0.14%)

13:28
05/19/19
05/19
13:28
05/19/19
13:28
Periodicals
Boeing says simulator software of 737 Max jets corrected, Reuters says »

Boeing has made…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

XOM

Exxon Mobil

$75.91

-0.44 (-0.58%)

13:17
05/19/19
05/19
13:17
05/19/19
13:17
Periodicals
Exxon evacuates all foreign staff from Iraqi oilfield, Reuters says »

Exxon Mobil has evacuated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

TSN

Tyson Foods

$82.50

-0.48 (-0.58%)

, MCD

McDonald's

$199.20

-0.71 (-0.36%)

13:06
05/19/19
05/19
13:06
05/19/19
13:06
Periodicals
Meat prices set to climb amid swine fever, WSJ reports »

African swine fever,…

TSN

Tyson Foods

$82.50

-0.48 (-0.58%)

MCD

McDonald's

$199.20

-0.71 (-0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 29

    May

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$285.98

-1.87 (-0.65%)

13:02
05/19/19
05/19
13:02
05/19/19
13:02
Periodicals
Deutsche Bank staff saw suspicious activity in Trump account, NYTimes says »

Anti-money laundering…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$285.98

-1.87 (-0.65%)

DB

Deutsche Bank

$7.58

-0.08 (-1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

MDCO

The Medicines Co.

$33.01

-0.19 (-0.57%)

12:51
05/19/19
05/19
12:51
05/19/19
12:51
Hot Stocks
The Medicines Co. announces interim results from ORION-3 extension study »

The Medicines Co.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

ACAD

Acadia

$24.97

-0.69 (-2.69%)

12:44
05/19/19
05/19
12:44
05/19/19
12:44
Hot Stocks
Acadia presents Phase 2 CLARITY results for Pimavanserin »

Acadia Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PINS

Pinterest

$26.69

0.68 (2.61%)

08:37
05/18/19
05/18
08:37
05/18/19
08:37
Periodicals
Pinterest committed 'cardinal sin' for newly public company, Barron's says »

Pinterest released its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KSHB

KushCo Holdings

$0.00

(0.00%)

08:32
05/18/19
05/18
08:32
05/18/19
08:32
Periodicals
Pot paraphernalia companies taking hit from tariffs, Barron's says »

The U.S.-China trade…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

JWN

Nordstrom

$37.09

0.16 (0.43%)

08:24
05/18/19
05/18
08:24
05/18/19
08:24
Periodicals
Nordstrom stock a 'can't miss bargain.' Barron's says »

Nordstrom remains the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 23

    May

NTDOY

Nintendo

$0.00

(0.00%)

, TTWO

Take-Two

$106.76

-0.81 (-0.75%)

08:10
05/18/19
05/18
08:10
05/18/19
08:10
Periodicals
Take-Two 'winning the game,' Barron's says »

Videogame stocks are down…

NTDOY

Nintendo

$0.00

(0.00%)

TTWO

Take-Two

$106.76

-0.81 (-0.75%)

DIS

Disney

$135.04

-0.46 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 29

    May

  • 06

    Jun

  • 08

    Jun

  • 10

    Jun

  • 10

    Jun

  • 10

    Jun

  • 11

    Jun

  • 12

    Jun

  • 24

    Jun

  • 13

    Nov

TPR

Tapestry

$30.78

-0.56 (-1.79%)

, REGN

Regeneron

$304.81

-4.69 (-1.52%)

08:01
05/18/19
05/18
08:01
05/18/19
08:01
Periodicals
Regeneron, Tapestry among cheap stocks to ride out trade war, Barron's says »

Applied Materials (AMAT),…

TPR

Tapestry

$30.78

-0.56 (-1.79%)

REGN

Regeneron

$304.81

-4.69 (-1.52%)

SCHW

Charles Schwab

$43.21

-0.94 (-2.13%)

BWA

BorgWarner

$36.27

-0.375 (-1.02%)

AMAT

Applied Materials

$42.72

-1.56 (-3.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 29

    May

  • 31

    May

  • 06

    Jun

  • 14

    Jun

  • 26

    Jun

  • 25

    Jul

MT

ArcelorMittal

$16.37

-0.485 (-2.88%)

, CLF

Cleveland-Cliffs

$10.02

-0.08 (-0.79%)

07:25
05/18/19
05/18
07:25
05/18/19
07:25
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

MT

ArcelorMittal

$16.37

-0.485 (-2.88%)

CLF

Cleveland-Cliffs

$10.02

-0.08 (-0.79%)

SCHN

Schnitzer Steel

$23.16

0.42 (1.85%)

BRSS

Global Brass and Copper

$43.09

-0.01 (-0.02%)

LXFR

Luxfer

$25.41

-0.44 (-1.70%)

MTRN

Materion

$66.36

0.155 (0.23%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$14.84

-0.01 (-0.07%)

F

Ford

$10.29

-0.1 (-0.96%)

GM

General Motors

$37.00

-0.36 (-0.96%)

HMC

Honda

$25.64

-0.135 (-0.52%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$118.40

-1.44 (-1.20%)

VWAGY

Volkswagen

$0.00

(0.00%)

SHOO

Steven Madden

$31.49

-0.37 (-1.16%)

GIII

G-III Apparel

$31.82

-0.35 (-1.09%)

IIVI

II-VI

$32.66

-1.64 (-4.78%)

LITE

Lumentum

$46.30

-4.15 (-8.23%)

MU

Micron

$36.06

-1.37 (-3.66%)

WDC

Western Digital

$44.62

-0.82 (-1.80%)

COHR

Coherent

$121.28

-5.22 (-4.13%)

LASR

nLight

$21.21

-1.27 (-5.65%)

VECO

Veeco

$12.50

-0.25 (-1.96%)

NPTN

NeoPhotonics

$3.83

-0.7 (-15.45%)

AAPL

Apple

$188.97

-0.93 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 22

    May

  • 23

    May

  • 23

    May

  • 24

    May

  • 28

    May

  • 29

    May

  • 03

    Jun

  • 04

    Jun

  • 04

    Jun

  • 05

    Jun

  • 05

    Jun

  • 07

    Jun

  • 10

    Jun

  • 13

    Jun

  • 14

    Jun

  • 09

    Jul

  • 24

    Jul

  • 31

    Jul

  • 01

    Aug

  • 23

    Oct

WMT

Walmart

$100.88

-0.56 (-0.55%)

17:59
05/17/19
05/17
17:59
05/17/19
17:59
Hot Stocks
Walmart EVP Furner sells 10K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

  • 05

    Jun

  • 07

    Jun

  • 07

    Jun

  • 15

    Aug

  • 13

    Nov

XOM

Exxon Mobil

$75.91

-0.44 (-0.58%)

, REPYY

Repsol

$0.00

(0.00%)

17:56
05/17/19
05/17
17:56
05/17/19
17:56
Periodicals
Exxon Gulf of Mexico sale gets interest from Repsol, Ineos, Bloomberg says »

Exxon Mobil (XOM) has…

XOM

Exxon Mobil

$75.91

-0.44 (-0.58%)

REPYY

Repsol

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 29

    May

IEF

iShares 7-10 Year Treasury Bond ETF

$106.74

0.04 (0.04%)

, SHY

iShares 1-3 Year Treasury Bond

$84.15

0.02 (0.02%)

17:43
05/17/19
05/17
17:43
05/17/19
17:43
General news
Weekly CFTC Commitment of Traders highlights »

2-YEAR U.S. TREASURY net…

IEF

iShares 7-10 Year Treasury Bond ETF

$106.74

0.04 (0.04%)

SHY

iShares 1-3 Year Treasury Bond

$84.15

0.02 (0.02%)

SPY

SPDR S&P 500 ETF Trust

$285.98

-1.87 (-0.65%)

SLV

iShares Silver Trust

$13.52

-0.14 (-1.02%)

GLD

SPDR Gold Shares

$120.64

-0.86 (-0.71%)

FXE

Euro Currency Trust

$106.35

-0.13 (-0.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$285.98

-1.87 (-0.65%)

17:39
05/17/19
05/17
17:39
05/17/19
17:39
Periodicals
IMF's Lagarde: U.S.-China trade spat may be risk to global economy, Reuters says »

IMF managing director…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$285.98

-1.87 (-0.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HIG

Hartford Financial

$53.58

-0.02 (-0.04%)

17:34
05/17/19
05/17
17:34
05/17/19
17:34
Syndicate
Breaking Syndicate news story on Hartford Financial »

Hartford Financial files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jun

AFH

Atlas Financial

$0.91

0.0225 (2.53%)

17:33
05/17/19
05/17
17:33
05/17/19
17:33
Hot Stocks
Atlas Financial receives filing delinquency notice from Nasdaq »

Atlas Financial received…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WES

Western Gas Partners

$30.60

-0.155 (-0.50%)

17:29
05/17/19
05/17
17:29
05/17/19
17:29
Syndicate
Breaking Syndicate news story on Western Gas Partners »

Western Gas Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$354.99

0.5 (0.14%)

17:24
05/17/19
05/17
17:24
05/17/19
17:24
Hot Stocks
Boeing awarded $163.91M Navy contract modification »

Boeing has been awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

LMT

Lockheed Martin

$338.10

-2.39 (-0.70%)

17:18
05/17/19
05/17
17:18
05/17/19
17:18
Hot Stocks
Lockheed Martin subsidiary awarded $1.13B Navy contract modification »

Sikorsky, a Lockheed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.